Jim Cramer: AbbVie Did 'Much, Much Better Than Expected'

Author:
Publish date:
Video Duration:
25

AbbVie  (ABBV) - Get Report posted earnings on Friday.

AbbVie said net earnings for the three months ended in September were $2.31 billion, or $1.29 a share, vs. $1.88 billion, or $1.26 a share, in the comparable year-earlier quarter.

On an adjusted basis, AbbVie earned $2.83 a share, above the $2.76 a share expected by analysts polled by FactSet.

Global sales jumped 52% to $12.9 billion vs. $8.4 billion a year ago, also ahead of analysts' forecasts of sales of $12.7 billion.

U.S. sales of the company's blockbuster arthritis treatment Humira rose 4.1% to $5.14 billion as U.S. gains offset international declines.

Net revenue from its hematologic oncology portfolio, meanwhile, came in at $1.72 billion, an increase of more than 16%, thanks to strong global sales of its Imbruvica and Venclexta cancer-fighting treatments.

Revenue from Botox used in cosmetic treatments came in at $393 million; revenue from AbbVie's "aesthetics" portfolio totaled $967 million, AbbVie said.

You can follow Jim Cramer and Katherine Ross on Twitter at @JimCramer and @byKatherineRoss. Read more from Katherine Ross here.

Latest Videos From TheStreet and Jim Cramer: